Latest Insider Transactions at Bluebird Bio, Inc. (BLUE)
This section provides a real-time view of insider transactions for Bluebird Bio, Inc. (BLUE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of bluebird bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of bluebird bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2025
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,625
-100.0%
|
-
|
|
Jun 02
2025
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
John O Agwunobi |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Najoh Tita Reid |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Richard A Colvin Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,666
-100.0%
|
-
|
|
Jun 02
2025
|
Richard A Colvin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
Mark Vachon |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Andrew Obenshain President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24,120
-100.0%
|
-
|
|
Jun 02
2025
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
14,820
+50.0%
|
-
|
|
Jun 02
2025
|
Elisabeth Leiderman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
O. James Sterling Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,500
-100.0%
|
-
|
|
Jun 02
2025
|
O. James Sterling Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
Thomas J Klima |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,964
-100.0%
|
-
|
|
Jun 02
2025
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Jun 02
2025
|
Charlotte Jones Burton |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Nick Leschly |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,245
-100.0%
|
-
|
|
Jun 02
2025
|
Michael Cloonan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,867
-100.0%
|
-
|
|
Jun 02
2025
|
Richard A. Paulson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,323
-100.0%
|
-
|
|
May 30
2025
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,143
-26.78%
|
-
|
|
May 30
2025
|
John O Agwunobi |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,323
-51.52%
|
-
|
|
May 30
2025
|
Najoh Tita Reid |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,163
-48.3%
|
-
|
|
May 30
2025
|
Richard A Colvin Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,552
-46.02%
|
-
|
|
May 30
2025
|
Mark Vachon |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,252
-50.14%
|
-
|
|
May 30
2025
|
Andrew Obenshain President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,027
-49.26%
|
-
|
|
May 30
2025
|
Elisabeth Leiderman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,112
-47.18%
|
-
|
|
May 30
2025
|
Thomas J Klima |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,414
-43.34%
|
-
|
|
May 30
2025
|
Charlotte Jones Burton |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
928
-42.71%
|
-
|
|
May 30
2025
|
Nick Leschly |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
8,434
-100.0%
|
-
|
|
May 30
2025
|
Nick Leschly |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,416
-92.05%
|
-
|
|
May 30
2025
|
Richard A. Paulson |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
155
-10.49%
|
-
|
|
Mar 03
2025
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
921
-4.78%
|
$2,763
$3.92 P/Share
|
|
Mar 03
2025
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
500
-5.97%
|
$1,500
$3.92 P/Share
|
|
Mar 03
2025
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
584
-7.13%
|
$1,752
$3.92 P/Share
|
|
Feb 10
2025
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
763
+3.81%
|
-
|
|
Feb 03
2025
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
86
-0.46%
|
$602
$7.39 P/Share
|
|
Feb 03
2025
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Open market or private sale
|
Direct |
238
-5.02%
|
$1,666
$7.39 P/Share
|
|
Feb 03
2025
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
64
-0.78%
|
$448
$7.39 P/Share
|
|
Feb 03
2025
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
122
-1.44%
|
$854
$7.39 P/Share
|
|
Jan 06
2025
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
140
-0.75%
|
$1,260
$9.24 P/Share
|
|
Jan 06
2025
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19
-0.23%
|
$171
$9.24 P/Share
|
|
Dec 10
2024
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,824
-1.68%
|
$0
$0.42 P/Share
|
|
Dec 10
2024
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
971
-0.26%
|
$0
$0.42 P/Share
|
|
Nov 06
2024
|
Najoh Tita Reid |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+34.08%
|
-
|
|
Nov 06
2024
|
Elisabeth Leiderman |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+34.56%
|
-
|
|
Nov 06
2024
|
John O Agwunobi |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+32.65%
|
-
|
|
Nov 06
2024
|
Charlotte Jones Burton |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+36.42%
|
-
|
|
Nov 06
2024
|
Richard A. Paulson |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+45.72%
|
-
|
|
Nov 06
2024
|
Nick Leschly |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+7.31%
|
-
|
|
Nov 06
2024
|
Mark Vachon |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+33.27%
|
-
|
|
Sep 30
2024
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
34,780
-8.48%
|
$0
$0.53 P/Share
|